AXON Neuroscience

AXON Neuroscience is a pioneering, privately-held biotech company at the forefront of tau-targeted therapies for Alzheimer's disease. Founded on the foundational tau research of Professor Michal Novák, the company has advanced its lead active immunotherapy candidate, AADvac1, through a successful Phase II clinical trial. With a deep scientific heritage and a specialized team, AXON is positioned as a key player in addressing one of medicine's largest unmet needs through its proprietary tau immunotherapy platform.

Tau-targeted immunotherapy platform utilizing both active immunization (vaccines) and passive immunization (monoclonal antibodies) designed to selectively target pathological, truncated forms of tau protein while sparing healthy tau.

AXON is a pioneer in tau immunotherapy but now competes in a growing field with large pharmaceutical companies (e.g., Biogen, Eli Lilly, Roche) and other biotechs developing tau-targeting antibodies and vaccines. Its key competitive differentiators are its foundational science, specific focus on truncated 'Alzheimer tau,' and first-in-class active vaccine approach with published Phase II data.